Loading...
Loading...
Browse all stories on DeepNewz
VisitPharmaceutical company saving most from Medicare negotiation by 2026?
Novo Nordisk • 25%
AstraZeneca • 25%
Pfizer • 25%
Other • 25%
Financial reports from pharmaceutical companies or analysis by financial experts
Medicare to Negotiate Prices of 15 Drugs Including Ozempic and Wegovy, New Prices Effective in 2027
Jan 17, 2025, 01:39 PM
The US government announced that Medicare will negotiate prices for an additional 15 drugs, including Novo Nordisk's blockbuster diabetes and weight loss medications Ozempic, Wegovy, and Rybelsus, with new prices to take effect in 2027. These drugs were selected in the second round of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act. The negotiations aim to lower prescription costs for millions of seniors on Medicare, following the first round that delivered price reductions of 40% to 80%. Other drugs selected include Trelegy Ellipta, Xtandi, Pomalyst, Ibrance, Ofev, Linzess, Calquence, Austedo, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet, Janumet XR, and Otezla. The initiative is expected to save the government more than $200 billion over a decade.
View original story
Amgen • 25%
Bristol-Myers Squibb • 25%
Novo Nordisk • 25%
Other • 25%
Ozempic • 25%
Janumet • 25%
Other • 25%
Wegovy • 25%
Ozempic • 25%
Xtandi • 25%
Trelegy Ellipta • 25%
Wegovy • 25%
Novo Nordisk • 25%
Other • 25%
GlaxoSmithKline • 25%
Pfizer • 25%
Ozempic • 25%
Trelegy Ellipta • 25%
Wegovy • 25%
Pomalyst • 25%
Pomalyst • 25%
Trelegy Ellipta • 25%
Wegovy • 25%
Ozempic • 25%
No significant reduction • 1%
UnitedHealth • 33%
Cigna • 33%
CVS • 33%
Cardiovascular drugs • 25%
Insulin • 25%
Other • 25%
Cancer drugs • 25%
Other • 25%
Novo Nordisk • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Cigna • 33%
No lawsuits filed • 1%
UnitedHealth • 33%
CVS • 33%
Ozempic • 25%
Other • 25%
Rybelsus • 25%
Wegovy • 25%